Literature DB >> 28693279

MicroRNA-215 acts as a tumor suppressor in breast cancer by targeting AKT serine/threonine kinase 1.

Jian Yao1, Ping Zhang1, Jin Li1, Wei Xu1.   

Abstract

There are accumulating reports that microRNAs are dysregulated in a number of human cancer types, and that they may function as tumor suppressors or oncogenes in tumorigenesis and tumor development. microRNA-215 (miR-215) has been identified as a tumor suppressor in epithelial ovarian, pancreatic, non-small cell lung and colon cancer, whereas it may act as an oncogene in gastric and cervical cancer. The role of miR-215 in breast cancer carcinogenesis and progression has yet to be elucidated. In the present study, the expression level of miR-215 was determined in breast cancer tissues and cell lines using the reverse transcription-quantitative polymerase chain reaction. The effects of miR-215 overexpression on proliferation and the invasive capacity of breast cancer cells were assessed using MTT and cell invasion assays. The results revealed that miR-215 was significantly downregulated in breast cancer tissues and cell lines. Restoration of miR-215 expression inhibited the proliferation and invasion of breast cancer cells. The underlying molecular mechanism for the suppression of proliferation and invasion by miR-215 was investigated. AKT serine/threonine kinase 1 (AKT1) was validated as a novel direct target of miR-215, and the effect of AKT1 small interfering RNA mimicked the effect of miR-215 overexpression in breast cancer cells. These results indicated that miR-215 acted as a tumor suppressor, and that its downregulation in tumor tissues may contribute to the carcinogenesis and progression of breast cancer, indicating that miR-215 may be a novel therapeutic target for the treatment of breast cancer.

Entities:  

Keywords:  AKT serine/threonine kinase; breast cancer; microRNA-215; targeted therapy; tumor suppressor

Year:  2017        PMID: 28693279      PMCID: PMC5494665          DOI: 10.3892/ol.2017.6200

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  40 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Small molecule compounds targeting miRNAs for cancer therapy.

Authors:  Paloma Del C Monroig; Lu Chen; Shuxing Zhang; George A Calin
Journal:  Adv Drug Deliv Rev       Date:  2014-09-17       Impact factor: 15.470

3.  miR-185 suppresses tumor proliferation by directly targeting E2F6 and DNMT1 and indirectly upregulating BRCA1 in triple-negative breast cancer.

Authors:  Hailin Tang; Peng Liu; Lu Yang; Xinhua Xie; Feng Ye; Minqing Wu; Xiaoping Liu; Bo Chen; Lijuan Zhang; Xiaoming Xie
Journal:  Mol Cancer Ther       Date:  2014-10-15       Impact factor: 6.261

4.  AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells.

Authors:  M Sun; G Wang; J E Paciga; R I Feldman; Z Q Yuan; X L Ma; S A Shelley; R Jove; P N Tsichlis; S V Nicosia; J Q Cheng
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

Review 5.  MicroRNAs in Breast Cancer: One More Turn in Regulation.

Authors:  Pilar Eroles; Eduardo Tormo; Begoña Pineda; Estefanía Espin; Ana Lluch
Journal:  Curr Drug Targets       Date:  2016       Impact factor: 3.465

Review 6.  Cell survival and metastasis regulation by Akt signaling in colorectal cancer.

Authors:  Ekta Agarwal; Michael G Brattain; Sanjib Chowdhury
Journal:  Cell Signal       Date:  2013-04-18       Impact factor: 4.315

7.  Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer.

Authors:  Seigo Nakamura; Hiroshi Yagata; Shinji Ohno; Hiroshi Yamaguchi; Hiroji Iwata; Nobuyuki Tsunoda; Yoshinori Ito; Nahomi Tokudome; Masakazu Toi; Katsumasa Kuroi; Eiji Suzuki
Journal:  Breast Cancer       Date:  2009-08-01       Impact factor: 4.239

8.  MicroRNA-210 promotes proliferation and invasion of peripheral nerve sheath tumor cells targeting EFNA3.

Authors:  Zhengguang Wang; Bangliang Yin; Bing Wang; Zemin Ma; Weidong Liu; Guohua Lv
Journal:  Oncol Res       Date:  2013       Impact factor: 5.574

9.  MiR-215 modulates gastric cancer cell proliferation by targeting RB1.

Authors:  Yujie Deng; Zhenxia Huang; Yanjun Xu; Juan Jin; Wei Zhuo; Cheng Zhang; Xuting Zhang; Minhong Shen; Xiaoyi Yan; Liangjing Wang; Xiaojia Wang; Yibin Kang; Jianmin Si; Tianhua Zhou
Journal:  Cancer Lett       Date:  2013-08-24       Impact factor: 8.679

10.  miR-409-3p suppresses breast cancer cell growth and invasion by targeting Akt1.

Authors:  Guoqiang Zhang; Zengyan Liu; Hao Xu; Qifeng Yang
Journal:  Biochem Biophys Res Commun       Date:  2015-11-26       Impact factor: 3.575

View more
  15 in total

1.  miR-152 may function as an early diagnostic and prognostic biomarker in patients with cervical intraepithelial neoplasia and patients with cervical cancer.

Authors:  Dongmei Yang; Qiumei Zhang
Journal:  Oncol Lett       Date:  2019-04-09       Impact factor: 2.967

2.  Gld2 activity is regulated by phosphorylation in the N-terminal domain.

Authors:  Christina Z Chung; Nileeka Balasuriya; Emad Manni; Xuguang Liu; Shawn Shun-Cheng Li; Patrick O'Donoghue; Ilka U Heinemann
Journal:  RNA Biol       Date:  2019-05-05       Impact factor: 4.652

3.  The long noncoding RNA PCAT-1 links the microRNA miR-215 to oncogene CRKL-mediated signaling in hepatocellular carcinoma.

Authors:  Yanli Ren; Jinhua Shang; Jinliang Li; Wenjuan Liu; Zhao Zhang; Jupeng Yuan; Ming Yang
Journal:  J Biol Chem       Date:  2017-09-08       Impact factor: 5.157

4.  Barriers in systemic delivery and preclinical testing of synthetic microRNAs in animal models: an experimental study on miR-215-5p mimic.

Authors:  T Machackova; P Vychytilova-Faltejskova; K Souckova; R Laga; L Androvič; G Mixová; O Slaby
Journal:  Physiol Res       Date:  2021-05-12       Impact factor: 1.881

5.  Evaluation of Mir-224, Mir-215 and Mir-143 as Serum Biomarkers for HCV Associated Hepatocellular Carcinoma

Authors:  Samah Mamdouh; Fatma Khorshed; Tarek Aboushousha; Hussam Hamdy; Ayman Diab; Mohamed Seleem; Mohamed Saber
Journal:  Asian Pac J Cancer Prev       Date:  2017-11-26

Review 6.  Precision Medicine for CRC Patients in the Veteran Population: State-of-the-Art, Challenges and Research Directions.

Authors:  Shyam S Mohapatra; Surinder K Batra; Srinivas Bharadwaj; Michael Bouvet; Bard Cosman; Ajay Goel; Wilma Jogunoori; Michael J Kelley; Lopa Mishra; Bibhuti Mishra; Subhra Mohapatra; Bhaumik Patel; Joseph R Pisegna; Jean-Pierre Raufman; Shuyun Rao; Hemant Roy; Maren Scheuner; Satish Singh; Gitanjali Vidyarthi; Jon White
Journal:  Dig Dis Sci       Date:  2018-03-23       Impact factor: 3.199

7.  Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors.

Authors:  Florian Bösch; Alexandr V Bazhin; Sabine Heublein; Katharina Brüwer; Thomas Knösel; Florian P Reiter; Christoph J Auernhammer; Markus O Guba; Christine Spitzweg; Jens Werner; Martin K Angele
Journal:  BMC Cancer       Date:  2019-06-13       Impact factor: 4.430

8.  The better effects of microbubble ultrasound transfection of miR-940 on cell proliferation inhibition and apoptosis promotion in human cervical cancer cells.

Authors:  Xiaojun Xiao; Yujuan Zhang; Qi Lin; Keli Zhong
Journal:  Onco Targets Ther       Date:  2019-08-21       Impact factor: 4.147

9.  miR-215 Enhances HCV Replication by Targeting TRIM22 and Inactivating NF-κB Signaling.

Authors:  Hui Tian; Zhenkun He
Journal:  Yonsei Med J       Date:  2018-06       Impact factor: 3.052

10.  MiR-215-5p Reduces Liver Metastasis in an Experimental Model of Colorectal Cancer through Regulation of ECM-Receptor Interactions and Focal Adhesion.

Authors:  Tana Machackova; Petra Vychytilova-Faltejskova; Kamila Souckova; Karolina Trachtova; Dominika Brchnelova; Marek Svoboda; Igor Kiss; Vladimir Prochazka; Zdenek Kala; Ondrej Slaby
Journal:  Cancers (Basel)       Date:  2020-11-26       Impact factor: 6.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.